Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Cash from Financing Activities (2020 - 2025)

Tango Therapeutics has reported Cash from Financing Activities over the past 6 years, most recently at $219.4 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $219.4 million for Q4 2025, up 22539.42% from a year ago — trailing twelve months through Dec 2025 was $222.5 million (up 366.81% YoY), and the annual figure for FY2025 was $222.5 million, up 366.81%.
  • Cash from Financing Activities for Q4 2025 was $219.4 million at Tango Therapeutics, up from $2.5 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for TNGX hit a ceiling of $327.8 million in Q3 2021 and a floor of -$746000.0 in Q2 2021.
  • Median Cash from Financing Activities over the past 5 years was $843500.0 (2022), compared with a mean of $35.6 million.
  • Biggest five-year swings in Cash from Financing Activities: plummeted 3081.02% in 2021 and later skyrocketed 70944.25% in 2023.
  • Tango Therapeutics' Cash from Financing Activities stood at -$120000.0 in 2021, then skyrocketed by 539.17% to $527000.0 in 2022, then surged by 178.37% to $1.5 million in 2023, then plummeted by 33.95% to $969000.0 in 2024, then skyrocketed by 22539.42% to $219.4 million in 2025.
  • The last three reported values for Cash from Financing Activities were $219.4 million (Q4 2025), $2.5 million (Q3 2025), and $581000.0 (Q2 2025) per Business Quant data.